Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.44 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | PYGB | P11216 | 6/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8818669 | 1.00 | LGALS1 (0.44) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL28357238 | 1.00 | LGALS1 (0.44) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL12471117 | 1.00 | LGALS1 (0.44) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL11215316 | 1.00 | LGALS1 (0.44) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL6932667 | 1.00 | LGALS1 (0.44) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL5793539 | 0.94 | LGALS3 (0.48) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| SCHEMBL21812094 | 0.81 | LGALS3 (0.48) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 | |
| Beta-D-Glucose SCHEMBL29038260 | 0.81 | LGALS1 (0.41) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| Beta-D-Glucose SCHEMBL5687444 | 0.81 | LGALS1 (0.41) | LGALS1LGALS3LGALS9LGALS8LMNA | |
| SCHEMBL24634747 | 0.79 | LGALS1 (0.45) | LGALS1LGALS3LGALS9LGALS8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57077620-A | — | — | None | — | — | JP | disclosed |
| US-20160081336-A1 | MEDIUM WITH A PLANT NON-METABOLIZABLE SUGAR FOR IMPROVING SEED GERMINATION | WEYERHAEUSER NR COMPANY (US) | 2016-03-24 | — | — | US | disclosed |
| US-20030229028-A1 | Methods and compositions for reducing side effects in chemotherapeutic treatments | GALECTIN THERAPEUTICS, INC. | 2003-12-11 | — | — | US | disclosed |
| EP-1363673-A2 | COMPOSITIONS FOR REDUCING SIDE EFFECTS IN CHEMOTHERAPEUTIC TREATMENTS | Pro-Pharmaceuticals, Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| US-6642205-B2 | Administering conjugate such as N-(beta-D-galactopyranosyl -(1-4)-beta-O-D-sorbityl)doxorubicin, wherein chemotherapeutic treatment includes adriamycin | PRO-PHARMACEUTICALS, INC. | 2003-11-04 | — | — | US | disclosed |
| WO-2002026262-A9 | COMPOSITIONS FOR REDUCING SIDE EFFECTS IN CHEMOTHERAPEUTIC TREATMENTS | PRO PHARMACEUTICALS INC (US) | 2003-03-20 | — | — | WO | disclosed |
| US-20020068077-A1 | Methods and compositions for reducing side effects in chemotherapeutic treatments | GALECTIN THERAPEUTICS, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002026262-A2 | COMPOSITIONS FOR REDUCING SIDE EFFECTS IN CHEMOTHERAPEUTIC TREATMENTS | PRO-PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| JP-S5777620-A | CARCINOSTATIC AGENT | WATANABE ATSUSHI | 1982-05-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068077-A1 | Methods and compositions for reducing side effects in chemotherapeutic treatments | PAICS, B3GAT3, GALE | LGALS1 145/4885LGALS3 185/4885LGALS9 307/4885 |
| US-20160081336-A1 | MEDIUM WITH A PLANT NON-METABOLIZABLE SUGAR FOR IMPROVING SEED GERMINATION | NEFM, MGAM, NANS | LGALS1 1033/4885LGALS3 1667/4885LGALS9 1414/4885 |
| US-20030229028-A1 | Methods and compositions for reducing side effects in chemotherapeutic treatments | PAICS, B3GAT3, GALE | LGALS1 145/4885LGALS3 185/4885LGALS9 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.